Amanat Acquisition, a blank check company targeting biotech and life sciences, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The company plans to raise $75 million by offering 7.5 million shares at $10. The offering does not contain warrants or rights.
Amanat Acquisition is led Chairman Sandeep Kulkarni, an experienced biotech executive who currently serves as CEO of Zura Bio, and CEO and Director Pavan Cheruvu, who previously served as CEO of Bitterroot Bio and Sio Gene Therapies. The SPAC plans to target the healthcare industry, particularly the biotechnology and life science sectors.
The Westfield, NJ-based company was founded in 2026. It plans to list on the Nasdaq under the symbol AMAN. Amanat Acquisition filed confidentially on March 18, 2026. Leerink Partners is the sole bookrunner on the deal.
